




# PHARMACEUTICAL 2021

**BRISTOL MYERS SQUIBB CO**  
Rank 244 of 402





RealRate

# PHARMACEUTICAL 2021

## BRISTOL MYERS SQUIBB CO Rank 244 of 402



The relative strengths and weaknesses of BRISTOL MYERS SQUIBB CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BRISTOL MYERS SQUIBB CO compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 137% points. The greatest weakness of BRISTOL MYERS SQUIBB CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is 56%, being 8.9% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	30,192,000
Cost of Goods Sold	11,773,000
Intangible Assets	73,790,000
Liabilities, Current	19,080,000
Liabilities, Non-Current	56,112,000
Other Assets	8,613,000
Other Compr. Net Income	-339,000
Other Expenses	20,936,000
Other Liabilities	5,407,000
Other Net Income	0
Other Revenues	42,518,000
Property and Equipment	5,886,000
Research and Development	11,143,000
Selling, General and Administrative Expense	7,661,000

Output Variable	Value in 1000 USD
Assets	118,481,000
Liabilities	80,599,000
Expenses	51,513,000
Revenues	42,518,000
Stockholders Equity	37,882,000
Net Income	-8,995,000
Comprehensive Net Income	-9,164,500
Economic Capital Ratio	56%